FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Cathepsin topics
Protease Inhibitor
Protease Inhibitors
Atherosclerosis
Recombinant
Osteoarthritis
Rheumatoid Arthritis
Steoporosis
Osteoporosis
Polypeptide
Nanoparticle
Fluorescence
Inflammatory Disease
Liver Diseases
Enterovirus
Virus Like Particle

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cathepsin patents



      
           
This page is updated frequently with new Cathepsin-related patent applications. Subscribe to the Cathepsin RSS feed to automatically get the update: related Cathepsin RSS feeds. RSS updates for this page: Cathepsin RSS RSS


Date/App# patent app List of recent Cathepsin-related patents
09/11/14
20140256743
 Cathepsin cysteine protease inhibitors patent thumbnailCathepsin cysteine protease inhibitors
This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins k, l, s and b. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis..
09/11/14
20140256698
 Cathepsin inhibitors patent thumbnailCathepsin inhibitors
The present invention is directed to inhibitors of cathepsins and the methods for using and making such inhibitors.. .
08/14/14
20140227188
 Compositions and methods for using cathepsin e cleavable substrates patent thumbnailCompositions and methods for using cathepsin e cleavable substrates
Provided herein are compositions and kits comprising a therapeutic agent linked to a cleavable substrate, wherein the cleavable substrate is capable of being cleaved by cathepsin e. Also provided are methods of treating one or more symptoms of a disease or disorder characterized by expression of cathepsin e in a subject and methods of eliminating a cancer cell characterized by expression of cathepsin e using the provided compositions and kits.
08/14/14
20140227175
 Cathepsin-binding compounds bound to a carrier and their diagnostic use patent thumbnailCathepsin-binding compounds bound to a carrier and their diagnostic use
The invention relates to cathepsin-binding compounds bound to a carrier comprising a diagnostic moiety, for use in the diagnosis of inflammatory diseases, and/or for use in the diagnosis of neoplastic diseases, wherein the cathepsin-binding compound binds to inflammatory cells of the tumour stroma. The invention also relates to cathepsin b-targeting compounds and cathepsin b-binding and liposome-binding compounds..
08/07/14
20140221654
 Protease inhibitors patent thumbnailProtease inhibitors
Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.. .
08/07/14
20140221478
 Di-fluoro containing compounds as cysteine protease inhibitors patent thumbnailDi-fluoro containing compounds as cysteine protease inhibitors
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins b, k, l, f, and s, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them..
08/07/14
20140221472
 Use of myricetin or derivatives thereof as a cathepsin k inhibitor patent thumbnailUse of myricetin or derivatives thereof as a cathepsin k inhibitor
This invention is directed to a novel inhibitor on collagen degradation caused by the activity of a human cathepsin k rising. In particular, the inhibitor is myricetin or derivatives thereof.
07/31/14
20140213531
 Template-fixed beta-hairpin peptidomimetics with protease inhibitory activitiy patent thumbnailTemplate-fixed beta-hairpin peptidomimetics with protease inhibitory activitiy
Wherein z is a chain of 11 α-amino acid residues which, depending on their positions in the chain (counted starting from the n-terminal amino acid) are gly, or pro, or pro(4nhcophe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to inhibit proteases, in particular serine proteases, especially cathepsin g or elastase or tryptase. These β-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy..
07/17/14
20140199326
 Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders patent thumbnailInhibitors of cathepsin s for prevention or treatment of obesity-associated disorders
The present invention relates to methods (and pharmaceutical compositions) for treating and/or preventing for obesity associated disorders, particularly related to a deregulation of glucose homeostasis, by administrating cathepsin s inhibitors. The invention also relates to methods for diagnosing insulin resistance and glucose tolerance by measuring cathepsin s levels in a biological sample obtained from a subject..
07/17/14
20140199320
 Modulators of the nlrp3 inflammasome il-1beta pathway for the prevention and treatment of acne patent thumbnailModulators of the nlrp3 inflammasome il-1beta pathway for the prevention and treatment of acne
The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of il-1β, il-1 receptor type 1, nlrp3, asc, caspase-1 and cathepsin b with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of il-1β, il-1 receptor type 1, il-1 receptor type 2, nlrp3, asc and caspase-1. Similarly, an interfering rna or an antisense modulator of gene expression of il-1β, i l-1β receptor type 1, nlrp3, asc, caspase-1 and cathepsin b are provided for the prevention or treatment of acne..
07/10/14
20140194445
Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Wherein a, d, e, l, g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example.
07/03/14
20140186471
Composition for inhibition of cathepsin k
The present invention relates to the a method of inhibiting bone resorption in a mammal in need thereof with an oral pharmaceutical composition comprising a cathepsin k inhibitor, or a pharmaceutically acceptable salt thereof, or a mixture thereof, according to a continuous schedule having a dosage interval of once weekly, biweekly, twice monthly or once monthly.. .
06/26/14
20140179924
Process for the preparation of cathepsin s inhibitors
Inhibitors of cathepsin s enzyme and their synthetic processes.. .
06/05/14
20140155383
Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
The present invention relates to the use of cathepsin k and/or cathepsin s inhibitors in a method for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure.. .
05/22/14
20140140930
Non-peptidic quenched fluorescent imaging probes
Methods and materials for the imaging of cells and tissues containing active proteases such as cathepsin are disclosed. The present materials include activity based probes that bind to an enzyme and are subsequently cleaved.
05/15/14
20140135328
Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Wherein a, d, e, l, g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example.
05/08/14
20140128616
Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
The present invention relates to compounds of the formula i, wherein a, d, e, g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example.
04/17/14
20140106369
Biomarkers for aggressive prostate cancer
The present invention relates to the field of biomarkers and, more specifically, to biomarkers useful in diagnosing aggressive prostate cancer. In specific embodiments, a method for diagnosing aggressive prostate cancer in a patient comprises (a) measuring the levels of one or more biomarkers in a sample collected from the patient; and (b) comparing the levels of the one or more biomarkers with predefined levels of the same biomarkers that correlate to a patient having aggressive prostate cancer and predefined levels of the same biomarkers that correlate to a patient not having aggressive prostate cancer, wherein a correlation to one of the predefined levels provides the diagnosis.
04/10/14
20140099280
Novel superactive il-33 fragments, and uses thereof
The present invention discloses novel active polypeptide fragments of human il-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin g, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.. .
02/13/14
20140044681
Cathepsin k as a marker for cartilage production, repair and regeneration
Ctsk is used as a marker to identify, track, and manipulate ctsk positive cartilaginous stem cells for cartilage repair and regeneration in vitro and in vivo.. .
02/06/14
20140038944
Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors
Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .
01/23/14
20140024038
Method and reagents for treating hepatic fibrosis and inflammation
The invention relates to methods for identifying an anti-fibrotic or anti-inflammatory agent comprising determining cathepsin s expression in activated hepatic stellate cells which have been exposed to a test compound and comparing expression to non-exposed hepatic stellate cells. The invention also relates to methods for treating a disorder characterised or caused by hepatic fibrosis or inflammation, comprising administering a cathepsin s inhibitor to a subject..
01/16/14
20140018421
Di-fluoro containing compounds as cysteine protease inhibitors
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins b, k, l, f, and s, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them..
12/19/13
20130337484
Method for detecting a wound infection
The present invention relates to a method for detecting a wound infection comprising the steps of: contacting a sample obtained from a wound with at least two substrates for at least two enzymes selected from the group consisting of lysozyme, elastase, cathepsin g and myeloperoxidase, and detecting a wound infection when a conversion of the at least two substrates with said at least two enzymes are determined.. .
12/05/13
20130324610
Cathepsin cysteine protease inhibitors
This invention relates to deuterated compounds which are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.. .
12/05/13
20130324584
Cathepsin c inhibitors
Disclosed are 4-amino-2-butenamides of formula (i) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the cathepsin c enzyme such as chronic obstructive pulmonary disease.. .
11/28/13
20130316955
Aminostatin derivatives for the treatment of arthrosis
The present invention relates to compounds of the formula (i) and in particular medicaments comprising at least one compound of the formula (i) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin d is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.. .
11/07/13
20130296605
Compositions and methods for inhibition of cathepsins
This invention is directed to compound of formula i and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin k or cathepsin l, will be therapeutically useful.. .
10/03/13
20130260391
Method of determining the protease cathepsin b in a biological sample
A method for determination of the potentially available activity of cathepsin b in a biological sample, including the activity of the active form of cathepsin b, the form of cathepsin b which can be activated from the pro-form procathepsin b being present in the sample, and the form of cathepsin b which can be activated and which is inhibited in the sample in its activity by protease inhibitor, whereby the procathepsin b being present in the sample is converted into the active form of cathepsin b, the free protease inhibitor for cathepsin b being present in the sample is depleted from the sample or its inhibitor function is suppressed, and the protease inhibitor is withdrawn from the inhibited form of cathepsin b, and subsequently the activity of the active cathepsin b in the sample is determined.. .
09/26/13
20130252311
Method for preparing virus-like particle and recombinant baculovirus used therein
A recombinant baculovirus is provided for preparing picornavirus virus-like particles (vlp), wherein chitinase a (chia) and cathepsin v (v-cath) genes of the recombinant baculovirus are functionally disrupted and the recombinant baculovirus includes a picornavirus capsid protein gene under control of a strong promoter, and includes a protease gene configured for encoding a protease for hydrolyzing the capsid protein under control of a weak promoter. The recombinant baculovirus of the present invention may adopt high five or sf-9 cells for manufacturing enterovirus virus-like particles with improved stability and higher yields in comparison with the conventional arts.
09/26/13
20130251640
Protease degradable polypeptides and uses thereof
Provided herein are polypeptides that are selectively cleaved by cathepsin e. Also provided are methods of detecting cathepsin e.
09/05/13
20130231349
Protease inhibitors
Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.. .
08/22/13
20130217766
Formulations for cathepsin k inhibitors
The instant invention relates to pharmaceutical compositions containing cathespin k inhibitors. Also disclosed are processes for making said pharmaceutical compositions..
08/15/13
20130210779
Method of identifying triple negative breast cancer
The present invention provides means for identifying or classifying breast tumors based on the levels of nuclear cathepsin-l (ctsl) and nuclear p53 binding protein (53bp1), and methods of treating thereof.. .
07/04/13
20130172327
Substituted n- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin c
And their use as inhibitors of cathepsin c, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory diseases.. .
07/04/13
20130172232
Cysteine protease inhibitors
For the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin s.. .
06/27/13
20130165344
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of cancer antigen ca 15-3, c-c motif chemokine 18, c-c motif chemokine 24, cathepsin d, c-x-c motif chemokine 13, c-c motif chemokine 8, interleukin-2 receptor alpha chain, insulin-like growth factor-binding protein 3, interleukin-11, matrix metalloproteinase-8, transforming growth factor alpha, igg1, and igg2 as diagnostic and prognostic biomarkers in renal injuries..
06/20/13
20130158018
Heteroaryl nitrile compounds useful as inhibitors of cathepsin-s
Disclosed are cathepsin-s reversible inhibitor compounds of the formula (i) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same..
06/13/13
20130150345
Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors
Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .
05/16/13
20130123512
Process for the preparation of proline derivatives
The proline derivatives of the formula i are preferential inhibitors of the cysteine protease cathepsin s and are therefore useful to treat metabolic diseases like diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease and diabetic nephropathy.. .
04/25/13
20130102562
Inhibition of cathepsin k activity and the treatment and prevention of disease
The present invention provides a candidate compound that is suitable for use in methods of treating animals (preferably mammals) and in the preparation of a medicament, wherein the candidate compound down regulates cathepsin k activity.. .
02/28/13
20130053416
3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Wherein ht, g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example.
02/28/13
20130053402
Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals
Wherein g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example.
02/21/13
20130046004
Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
The present invention relates to compounds of the formula i, wherein a, d, e, g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example.
02/07/13
20130035312
Cathepsin cysteine protease inhibiors
This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins k, l, s and b. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis..


Popular terms: [SEARCH]

Cathepsin topics: Protease Inhibitor, Protease Inhibitors, Atherosclerosis, Recombinant, Osteoarthritis, Rheumatoid Arthritis, Steoporosis, Osteoporosis, Polypeptide, Nanoparticle, Fluorescence, Inflammatory Disease, Liver Diseases, Enterovirus, Virus Like Particle

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cathepsin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cathepsin with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



2.312

2022

449687 - 0 - 45